The pipeline of antiviral T‐cell therapy: what's in the clinic and undergoing development

Virus‐specific T cells allow targeting of multiple pathogens in patients after hematopoietic stem cell transplantation and have demonstrated potential efficacy for cytomegalovirus, Epstein–Barr Virus, and adenovirus. Novel targets may include BK virus, JC virus, varicella zoster virus, human herpesvirus 6, Aspergillus, human parainfluenza virus‐3, herpes simplex virus Type I, Zika virus, and mycobacteria. Generation of patient‐specific products and third‐party products may expand feasibility of therapy.

• Publication year

  2020

• Venue

  Transfusion

• Publication date

  2020-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/trf.15501PMID 31469438PMCID PMC9359816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Generation of Zika virus-specific T cells from seropositive and virus-naïve donors for potential use as an autologous or "off-the-shelf" immunotherapeutic.

  2019cited by this paper
• Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders

  2019cited by this paper
• Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.

  2019cited by this paper
• Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus–Specific CD8+ T Cells

  2018cited by this paper
• Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy

  2018cited by this paper
• Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy.

  2017cited by this paper
• The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

  2017influential reference
• Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

  2017cited by this paper
• Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

  2016cited by this paper
• CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo

  2015cited by this paper
• Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.

  2015cited by this paper
• Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT

  2014cited by this paper
• Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

  2009cited by this paper
• Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

  2005cited by this paper

• BK viral infection: A review of management and treatment

  2023cites this paper
• Cellular Engineering

  2021cites this paper
• Novel treatments for progressive multifocal leukoencephalopathy.

  2020cites this paper
• Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation

  2020cites this paper
• Matched Family Donor Lymphocyte Infusions as First Cellular Therapy for Patients with Severe Primary T-cell Deficiencies.

  2020cites this paper
• Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies

  2020cites this paper
• Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections

  2019cites this paper